BACKGROUND Plasminogen activator inhibitor type 1 (PAI-1) plays an essential role in the fibrinolysis system and thrombosis. Population studies have reported that blood PAI-1 levels are associated with increased risk of coronary heart disease (CHD). However, it is unclear whether the association reflects a causal influence of PAI-1 on CHD risk. METHODS AND RESULTS To evaluate the association ...

BACKGROUND cag pathogenicity island (PAI) is reported to be a major virulence factor of Helicobacter pylori. AIM To characterise cagA and the cag PAI in Japanese H pylori strains. METHODS H pylori isolates from Japanese patients were evaluated for CagA by immunoblot, for cagA transcription by northern blot, and for cagA and 13 other cag PAI genes by Southern blot. cagA negative strains from...

PURPOSE Urokinase-type plasminogen activator (uPA) and its inhibitor, plasminogen activator inhibitor (PAI)-1, have been shown to be related to poor prognosis in a variety of malignant solid tumors. Studies on the prognostic relevance of uPA and PAI-1 in ovarian cancer, however, have been inconclusive. The current study tests the hypothesis that elevated expression of uPA and PAI-1 is associate...

Plasminogen activator inhibitor (PAI-1) is an anticancer agent that inhibits plasmin driven proteolysis, limiting angiogenesis and metastasis. In low concentrations it could induce cancer cell motility by interacting with urokinase (uPA), its receptor (uPAR), vitronectin and integrins. Active PAI-1 binds to uPA forming a complex with uPAR, while the latent form of PAI-1 does not. PAI-1 is found...

Bleeding diathesis is a common reason for investigation of the haemostatic system and in about 50% of the cases an abnormality is found. Plasminogen activator inhibitor type 1 (PAI-1) is an inhibitor of tissueand urokinase plasminogen activator (tPA/uPA). High PAI-1 levels are associated with arterial and venous thrombotic conditions but are also seen in pregnancy, inflammatory and infectious d...

Different weight amounts of graphene oxide (GO) were solution-dispersed with the precursor of polyimide (PI) and poly(amide-imide) (PAI) to synthesizen PI/GO or PAI/GO composite films after the imidization process. The addition of trimellitic anhydride chloride (TMAC) in PAI/GO matirx provides the interaction between amide group on PAI and carboxy/hydroxyl groups on GO.The effects of TMAC and G...

INTRODUCTION Plasminogen activator inhibitor 1 (PAI-1) is a key factor in trauma- and sepsis-induced coagulopathy. We examined how trauma-hemorrhage (TH) modulates PAI-1 responses in subsequent cecal ligation and puncture (CLP)-induced sepsis, and the association of PAI-1 with septic outcomes. METHODS Mice underwent TH and CLP 48 h later in three separate experiments. In experiment 1, mice we...

OBJECTIVE We previously reported that plasminogen activator inhibitor 1 (PAI-1), in the presence of vitronectin (VN), inhibits thrombin activity in vitro. Furthermore, we demonstrated in human atherosclerotic plaques the colocalization of thrombin, PAI-1, and VN, as well as activity of thrombin and PAI-1. Here, we show that PAI-1 is a local thrombin inhibitor in vivo. METHODS AND RESULTS We u...

Plasminogen activator inhibitor-1 (PAI-1) is the main inhibitor of plasminogen activators, such as tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA), and a major regulator of the fibrinolytic system. PAI-1 plays a pivotal role in acute thrombotic events such as deep vein thrombosis (DVT) and myocardial infarction (MI). The biological effects of PAI-1 exten...

Increased expression of plasminogen activator inhibitor-1 (PAI-1) in cancer patients is associated with unfavorable outcome, and the reason for this paradox has been poorly understood. We have previously reported elevated levels of PAI-1 in primary tumors of advanced neuroblastomas (Y. Sugiura et al., Cancer Res., 59: 1327-1336, 1999). Here we demonstrate that PAI-1 is coexpressed with the angi...